Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $8.45, for a total transaction of $96,727.15. Following the sale, the director now directly owns 7,188,563 shares of the company’s stock, […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total value of $421,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 […]
Elevatus Welath Management acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 24,650 shares of the company’s stock, valued at approximately $243,000. Other institutional investors also recently bought and sold shares of the […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now owns 863,524 shares […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the sale, the director now directly owns 7,229,861 shares in the […]